Vesugen

Research summary

Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from Vladimir Khavinson's peptide bioregulator research program, studied mainly for effects on vascular endothelial cells, including nitric-oxide- and prostaglandin-mediated vasorelaxation and markers of endothelial aging.

In vascular-endothelial-cell research, Vesugen has been studied for normalizing endothelin-1 levels, restoring gap-junction protein expression, and activating cell-proliferation-related gene expression in aged endothelium. A small, uncontrolled 41-patient study in people with vasculogenic erectile dysfunction reported improved arterial blood flow measurements after Vesugen treatment. This body of research comes primarily from the developing laboratory's own program and has not been broadly confirmed by independent controlled human trials.

Sources: PubMed 25051766 (endothelial aging); uncontrolled clinical case series. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.